Home › Bipolar Disorder › Illinois › Naperville
Bipolar Disorder clinical trials in Naperville, IL
3 studies for Bipolar Disorder are looking for participants at sites in and around Naperville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RecruitingPhase 3
- Baber Research Group, Naperville
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RecruitingPhase 4
- Neurocrine Clinical Site, Naperville
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RecruitingPhase 2
- Amr Conventions Research /ID# 272867, Warrenville · 3 mi away
About Bipolar Disorder
Bipolar disorder is a mood disorder that can cause intense mood swings. It's also called manic depression. Learn about the types, symptoms, treatment, and more.
More about Bipolar Disorder on MedlinePlus
Bipolar Disorder trials in other cities
- Houston, TX10 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Little Rock, AR6 studies
- Atlanta, GA6 studies
- Miami, FL5 studies
- Hialeah, FL5 studies
- Austin, TX5 studies
- Cambridge, MA5 studies
- Orange, CA5 studies
- Anaheim, CA4 studies
- Everett, WA4 studies
Other studies in Naperville
- Non-Small Cell Lung Cancer16 studies
- Lung Cancer13 studies
- Heart Failure13 studies
- Prostate Cancer10 studies
- Breast Cancer9 studies
- Cardiovascular Disease8 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Geographic Atrophy6 studies
- Macular Degeneration6 studies
- Pancreatic Cancer6 studies
- Cancer (all types)5 studies
- Atrial Fibrillation5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.